Fig. 2
ZOT5-1-Me and ZOT5-1-Et induced growth inhibition and lethality in glioblastoma and astrocytoma cell lines and COMPARE analysis of their mechanisms of action relative to reference anticancer drugs. (A) Cells were treated with an increasing concentration (10–8 to 10–4 M) of ZOT5-1-Me and ZOT5-1-Et for 48 h, and the analysis was performed thanks to the NCI-60 Cell Screen. Five dose–response curves in 3 glioblastoma (SF-295, SF-539, and SNB-75) and 3 astrocytoma (SF-268, SNB-19, and U251) cell lines are shown. NCI-60 analysis allows for the detection of both growth inhibition (values between 0 and 100) and lethality (values less than 0). A value of 100% represents no growth inhibition. The value of 0% indicates no cell growth throughout the experiment, corresponding to the number of cells at the beginning. The value of −50% means 50% lethality, and the value of 100% means that all cells are dead by treatment. GI50, the concentration required for 50% cell growth inhibition; TGI, the concentration required for total inhibition (0%); LC50, the concentration required for 50% cell death. (B) Comparison of the mechanism of ZOT5-1-Me and ZOT5-1-Et to FDA-approved and non-FDA-approved GBM anticancer drugs by COMPARE plots. ZOT5-1-Me and ZOT5-1-Et have a unique mechanism compared to known chemotherapeutics. High PCC (Pearson correlation coefficient) (> 0.8) shown in red in the matrix COMPARE figure, indicates these two drugs have similar mechanisms of anticancer action.
